Early predictors for the development of stroke-associated infection may identify patients at high risk and reduce post-stroke infection and mortality.
In 383 prospectively enrolled acute stroke patients we assessed time point and type of post-stroke infections (i.e. pneumonia, urinary tract infection (UTI) other infection (OI)). Blood samples were collected on admission, and days 1, and 3 to assess white blood cells (WBC), monocytes, C-reactive protein (CRP), procalcitonin (PCT), and copeptin. To determine the magnitude of association with the development of infections, odds ratios (OR) were calculated for each prognostic blood marker. The discriminatory ability of different predictors was assessed, by calculating area under the receiver operating characteristic curves (AUC). Prognostic models including the three parameters with the best performance were identified.
Of 383 patients, 66 (17.2%) developed an infection after onset of stroke. WBC, CRP, copeptin and PCT were all independent predictors of any infection, pneumonia and UTI developed at least 24 hours after measurements. The combination of the biomarkers WBC, CRP and copeptin (AUC: 0.92) and WBC, CRP and PCT (AUC: 0.90) showed a better predictive accuracy concerning the development of pneumonia during hospitalization compared to each marker by itself (p-Wald <0.0001).
Citation: Fluri F, Morgenthaler NG, Mueller B, Christ-Crain M, Katan M (2012) Copeptin, Procalcitonin and Routine Inflammatory Markers–Predictors of Infection after Stroke. PLoS ONE7(10): e48309. https://doi.org/10.1371/journal.pone.0048309
Editor: Thiruma V. Arumugam, University of Queensland, Australia
Received: July 12, 2012; Accepted: September 24, 2012; Published: October 31, 2012
Copyright: © 2012 Fluri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Swiss National Science Foundation (PBZHP3-130982, to MK) and the Fondation Leducq (career development grant, to MK). The funding institutions had no role in study design, data collection, analysis decision to publish, or preparation of the manuscript.
Competing interests: FF reports no disclosures. NM was employed by B.R.A.H.M.S., the manufacturer of the copeptin and procalcitonin-assays. BM, MCC and MK received payments from B.R.A.H.M.S. unrelated to this study. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Infection during the first days after ischemic stroke (IS) occurs in 25–65% of patients , . Pneumonia and urinary tract infection (UTI) are the most common infectious complications after IS . It has been suggested that the predominance of infections during the acute phase of stroke  is due to stroke-induced immunosuppression (SIS) . The central nervous system modulates the activity of the immune system through complex pathways that include the hypothalamic pituitary adrenal axis (HPAA), the vagus nerve, and the sympathetic nervous system , . Several studies found an independent association between stroke-associated infections (SAI) and poor functional outcome after IS –.
Therefore, early initiation of antibiotic treatments is recommended if infection is present . However, gold-standard clinical diagnostics are time-consuming and delay early antibiotic therapy. Thus, accurate and simply available prognostic markers for optimal risk stratification are needed. We therefore selected C-reactive protein (CRP), white blood cells (WBC), monocytes (Mcyt), as they represent the most commonly measured and well-established inflammatory markers in clinical routine. Procalcitonin (PCT) was selected to better discriminate infections from general inflammation , . Copeptin, a reliable stress marker  was selected because SIS may be mediated by changes in the neuroendocrine system. All these biomarkers are available immediately due to rapid analytic procedure.
We hypothesize that these blood markers are predictive for the development of post-stroke infections. First we planned to evaluate the prognostic value of each blood biomarker to predict infections in the acute phase of IS. Second, we aimed to identify the best prognostic model consisting of a batch of the best prognostic biomarkers. Thereafter, the prognostic value of this batch was compared to that of each prognostic biomarker alone.
Patients and Methods
The study has been approved by the local Ethics Committee at the University Hospital of Basel. All participants or their representative gave written informed consent for the study.
We performed a post-hoc analysis of a prospective cohort study . All patients with IS within 72 hours before admission at the Emergency Department, University Hospital of Basel, were eligible and prospectively enrolled (11/2006–11/2007). IS was confirmed by CT and/or MRI on admission. Neurological deficits were measured at presentation with the National Institutes of Health Stroke Scale (NIHSS) score.
Definition of Stroke-associated Infections
SAI was defined as any infection occurring within the first 5 days of hospital admission . Infections were diagnosed according to the criteria of the U.S. Centers for Disease Control and Prevention (CDC) . We distinguished between pneumonia, urinary tract infection (UIT) and “other infections” (OI). Pneumonia was diagnosed when at least one of each of the first and latter criteria was fulfilled: i) abnormal respiratory examination, pulmonary infiltrates in chest x-rays; ii) productive cough with purulent sputum, positive microbiological cultures from lower respiratory tract or blood cultures. Diagnosis of UTI was based on two of the following criteria: fever (≥38.0°C), urine sample positive for nitrite, leukocyturia (>40/µL), or significant bacteriuria (≥104/mL of an uropathogen). OI was defined if temperature was ≥38.0°C, white blood cell count was ≥11000/mL or CRP≥10 mg/L and an infectious manifestation was present. Diagnosis of infection was done by the treating physician during hospitalization and was then validated post-hoc using charts, both diagnosis by treating physicians as well as secondary validation was blinded to biomarker levels with the exception of WBC and CRP for the diagnosis of (OI). Time point of diagnosis was referred to the beginning of clinical symptoms, which lead to diagnostic work-up and resulted in the diagnosis of infection.
In order to exclude acute infections preceding stroke, patients with admission temperature ≥38°C, or patients reporting an infection lasting up to 3 days before onset of stroke or patients who required mechanical intubation were not included in the study.
Blood samples were collected on admission (baseline) within 72 hours from symptom onset, and 1, and 3 days after admission to assess WBC and Mcyt count, CRP level, PCT and copeptin. PCT serum concentration was measured using a commercially available time-resolved amplified cryptate emission technology assay (Kryptor PCT, Brahms, Hennigsdorf, Germany) . Measurement of copeptin was performed in a single batch with a commercial sandwich immunoluminometric assay (LUMItest CT-proAVP, B.R.A.H.M.S, Hennigsdorf/Berlin, Germany) . In patients who died within 5 days after admission, or in patients who were discharged before day 5, only data from admission or until the day of discharge were collected.
Descriptive statistics were expressed as means ± standard deviations, medians and quartiles or absolute and relative frequencies depending on their distribution. Group differences were assessed using the Kruskal-Wallis test or Chi 2-test. Logarithmic transformation was performed to obtain an approximately normal distribution for all parameters except temperature and Mcyt.
First, the association of the biomarkers measured at admission with the presences of infections developed within 5 days was assessed using simple logistic regression.
Second we calculated pooled logistic regression considering patients to be at risk until the manifestation of an infection or until day 5 whichever occurred first. Each of these models had one time dependent predictor variable, i.e., the measurement of a given blood parameter 1 or 2 days before the respective day of diagnosis of infection. To adjust for potential clustering of data within subjects, robust standard errors were computed using the method of Huber-White. Odds ratios (OR) and associated 95% confidence intervals (95%CI) refer to an increase of the respective parameter from the lowest to the highest quartile.
Third, we compared the discriminatory ability of different predictors by calculating receiver operating characteristic (ROC) analysis. Bootstrap methods were used to derive 95%CIs for AUCs, index of Youden and optimal cutpoints to statistically compare AUC’s of different predictors.
Forth, to assess the prognostic independence from age, NIHSS score (as indicator of stroke severity) and Charlson index (as indicator of comorbidity burden) as well as infratentorial and supratentorial infarct localization, we performed bivariate logistic regression (to avoid over-fitting) with these potential confounders.
Finally, we calculated 2 prediction models (batch 1 and 2) by including established inflammatory parameters (WBC and CRP) and either Copeptin or PCT, the 2 new makers. Since robust precision estimates were used, model comparisons could not be done using likelihood ratio tests but were based on Wald p-values.
P-values less than 0.05 were considered to indicate statistical significance. All calculations were performed using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA).
Of 383 patients with stroke, 66 (17.2%) developed an infection within 5 days after onset of stroke. Twenty (5.2%) patients suffered from pneumonia, 25 (6.5%) patients had UTI and 21 (5.5%) patients an OI (sepsis: 7 patients; phlebitis: 6 patients; gastroenteritis: 4 patients, erysipelas: 1 patient; panniculitis: 1 patient, colpitis: 2 patients). Baseline data are summarized in table 1.
Blood Biomarkers as Predictors of Post-stroke Infections
Copeptin, PCT, WBC and CRP-levels on admission predicted any infection, pneumonia and UTI in the acute phase of stroke. ORs and AUCs for each marker measured on admission (i.e. day 0) are provided in table 2. ORs to predict infections associated with nearest predictor measurements over time (i.e. performed 1 or 2 days prior to the onset of infection) are presented in table 3. After adjusting for either age, NIHSS, CI or infarct localization (infra−/supratentorial) in a bivariate model all biomarkers remained significant predictors (table 4).
Copeptin as a new prognostic marker for SAI was a strong predictor of any infection, pneumonia and UTI (table 3). Copeptin had the same prognostic accuracy compared to WBC, CRP, and the only statistical significant difference in AUCs was found when comparing WBC and copeptin regarding the outcome of OI (p = 0.02) (table 5).
Predictive Models for Post-stroke Infections
We defined two batches of the three parameters with highest AUC values for any infection, pneumonia, UTI and OI by combining WBC, CRP and copeptin (batch 1) as well as WBC, CRP and PCT (batch 2).
Batch 1 (WBC, CRP, copeptin) better predicted any infection (Wald-p<0.001) and pneumonia (Wald-p<0.001) than the best single predictor alone. However, batch 1 was not a better predictor of UTI (Wald-p = 0.058) and OI (Wald-p = 0.25) than WBC (table 6).
Batch 2 (WBC, CRP, PCT) better predicted any infection (Wald-p<0.001), pneumonia (Wald-p<0.001) and UTI (Wald-p = 0.014) than the best single predictor alone. However, batch 2 was not better in predicting OI compared to the best single predictor (Wald-p = 0.25) (table 6).
The value of rapidly available blood markers as predictors for SAI has not been studied extensively, although WBC, CRP and Mcyt are routinely measured within the first hours of admission. Copeptin and PCT measured on admission were good predictors of any infection, pneumonia and UTI in the present cohort. They showed a similar predictive value for future infection compared to WBC and CRP. In a recent study neither WBC, CRP, Mcyt nor PCT measured on admission were sensitive enough to reliably be associated with SAI . In another study, WBC and Mcyt count on admission did not differ between infected and non-infected stroke patients . Only on day 1 after stroke onset, body temperature  and WBC ,  became significantly associated with infections after stroke. However, in these studies the time point of diagnosis in relation to biomarker measurements was not taken into account. Therefore, they could not really establish the predictive value of these markers but rather their diagnostic accuracy at the time of infection. Moreover the sample size was somewhat small and associations might have been missed due to lack of power. To our knowledge our study is the first to assess the predictive value of these markers taking into account the time point of measurements as well as diagnosis.
In the present study, each laboratory parameter remained a strong predictor after adjusting for NIHSS, age and CI and infarct localization. This is an unexpected finding because age and stroke severity may also contribute to SIS and thus infection after acute ischemic stroke –. However, these biomarkers seem to add prognostic information beyond age, stroke severity and a higher CI as well as infarct localization.
Copeptin was a strong predictor for SAI on admission and during the acute phase of stroke. The predictive value of copeptin in respect of SAI was similar to that of established biomarkers of infection (i.e. WBC, CRP). This finding might be due to the association of copeptin with the activation of the HPAA: increased copeptin-levels probably indicate a high degree of stress and SIS, which means a higher susceptibility to develop an infection. The prognostic value of PCT was also in the range of WBC and CRP. In the literature PCT is a superior diagnostic marker in pneumonia and other bacterial infections when compared to WBC and CRP . However, the prognostic accuracy of a single PCT valueis limited . PCT might be rather a specific than a sensitive prognostic marker in predicting infections.
The combination of established inflammatory makers (WBC, CRP) combined with a biomarker of stress, i.e. copeptin or a biomarker of bacterial infection, i.e. PCT  improves prediction of SAI compared to the strongest prognostic marker alone. The combination of biomarkers probably reflects better the complexity of an infection than one biomarker alone and may lead to a more accurate prediction of a beginning but not yet clinically apparent infection.
The investigated biomarkers seem to detect infections before clinical or paraclinical signs prompt further diagnostic work-up leading to the diagnosis of infection. Thus, these markers may help in risk stratification and may select high-risk patients for intervention studies.
We are aware of the following limitations: First, our results are based ona single cohort and our findings need to be validated in an independent and larger cohort. Second, the sample size was relatively small when assessing subgroups of infection. The bivariate analysis may have a limited statistical power and validity underestimating possible effects of biomarkers and other potential predictors. Third, although WBC and CRP was not a criterion for making the diagnosis of pneumonia, any infection and UTI, one must take into account that WBC was one of three criteria for the diagnosis of the subgroup of OI. Therefore, the good predictive value of WBC - in the case of OI - is most probably due to incorporation bias. This, on the other hand, strengthens the predictive value of copeptin that might be underestimated compared to WBC in this study. Fourth, we are not able to proof causalities or provide more insights into pathomechanisms, to explain why these markers are good predictors of infections even before clinical signs occur. But even if these markers are only surrogates of underlying processes which predispose patients for infections, from a clinical standpoint we belief that the observed associations are very interesting since we identified accurate prognostic markers for risk stratification. Finally, the distinction between prediction and early diagnosis of infection is difficult. We are not able to differentiate whether the biomarkers investigated in this study might rather detect infections at an early state or predict vulnerability for future post-stroke infections, although we excluded patients with possible infection prior to the onset of stroke.
In summary, copeptin, PCT, WBC and CRP were good predictors of the development of any infection, pneumonia and UTI. The combination of the 3 biomarkers even improved the prognostic value by accurately separating patients with and without future infections already on admission. If validated in larger prospective studies the combination of these 3 biomarkers with best AUC values may add significant information for the early identification of high-risk patients. Future intervention studies could select patients with high-risk profiles according to these biomarker levels and these high-risk patients may proof to benefit from prophylactic antibiotic treatment.
We thank Dr. C. Schindler for statistical analyses and Prof. M. S. Elkind for his time and the appreciated comments as an expert in the field of inflammation and infection in stroke.
Conceived and designed the experiments: FF MK. Performed the experiments: FF MK. Analyzed the data: FF MK BM MCC. Contributed reagents/materials/analysis tools: BM MCC NGM. Wrote the paper: FF MK. assay development and measurement of copeptin and procalcitonin levels: NGM Supervision of the writing of the report: MCC, BM.
- 1. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, et al. (2005) The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial. Stroke 36: 1495–1500.
- 2. Vargas M, Horcajada JP, Obach V, Revilla M, Cervera A, et al. (2006) Clinical consequences of infection in patients with acute stroke: is it prime time for further antibiotic trials? Stroke 37: 461–465.
- 3. Weimar C, Roth MP, Zillessen G, Glahn J, Wimmer MLJ, et al. (2002) Complications following acute ischemic stroke. Eur Neurol 48: 133–140.
- 4. Chamorro A, Urra X, Planas AM (2007) Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke 38: 1097–1103.
- 5. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES (2000) The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52: 595–638.
- 6. Harms H, Reimnitz P, Bohner G, Werich T, Klingebiel R, et al. (2011) Influence of stroke localization on autonomic activation, immunodepression, and post-stroke infection. Cerebrovasc Dis 32: 552–560.
- 7. Aslanyan S, Weir CJ, Diener H-C, Kaste M, Lees KR (2004) Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol 11: 49–53.
- 8. Vermeij FH, Scholte op Reimer WJM, de Man P, van Oostenbrugge RJ, Franke CL, et al. (2009) Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey. Cerebrovasc Dis 27: 465–471.
- 9. Salat D, Delgado P, Alonso S, Ribó M, Santamarina E, et al. (2011) Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients. Eur Neurol 65: 82–87.
- 10. Emsley HCA, Smith CJ, Tyrrell PJ, Hopkins SJ (2008) Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit Care 9: 125–138.
- 11. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36: 396–407.
- 12. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, et al. (2007) Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 11: R38.
- 13. Katan M, Morgenthaler N, Widmer I, Puder JJ, König C, et al. (2008) Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 29: 341–346.
- 14. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, et al. (2009) Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 66: 799–808.
- 15. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16: 128–140.
- 16. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, et al. (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363: 600–607.
- 17. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112–119.
- 18. Wartenberg KE, Stoll A, Funk A, Meyer A, Schmidt JM, et al. (2011) Infection after acute ischemic stroke: risk factors, biomarkers, and outcome. Stroke Res Treat 2011: 830614.
- 19. Vogelgesang A, Grunwald U, Langner S, Jack R, Bröker BM, et al. (2008) Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. Stroke 39: 237–241.
- 20. Haeusler KG, Schmidt WUH, Föhring F, Meisel C, Helms T, et al. (2008) Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis 25: 50–58.
- 21. Chamorro A, Amaro S, Vargas M, Obach V, Cervera A, et al. (2006) Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatr 77: 1279–1281.
- 22. Chamorro A, Amaro S, Vargas M, Obach V, Cervera A, et al. (2007) Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci 252: 29–35.
- 23. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39: 206–217.
- 24. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, et al. (2011) Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 37: 384–392.